Article Text

PDF
Authors’ reply
  1. J M Carethers
  1. Correspondence to:
    Dr J M Carethers
    Division of Gastroenterology, University of California, San Diego, UC 303, MC 0063, La Jolla, CA 92093-0063, USA;jcarethers{at}ucsd.edu

Statistics from Altmetric.com

In my commentary (Gut 2006;55:759–61), that accompanied Jover et al’s paper (Gut 2006;55:848–55), we indicated several important issues regarding colon cancer microsatellite instability-high (MSI-H) and the influence of fluorouracil-based (FU) chemotherapy on patient survival that Iacopetta and Watanabe (Gut 2006:55:1671–2) raise in their letter, some of which need to be clarified. Most important is the separation of improved survival due to a patient’s tumour microsatellite instability status from improved survival due to FU treatment. A comparison of patients with MSI-H colon tumours who received chemotherapy and patients with MSI-H tumours who did not receive chemotherapy is the only way to separate out the influence of FU on survival in this group. This is because patients with MSI-H tumours already have an improved survival over those with microsatellite …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles